Macrogen, a precision medical biotechnology business, celebrated its 25th anniversary last Friday, unveiling its plan to open the “Macrogen 2.0 era” through high-speed growth and leaping to the digital healthcare business.

To this end, Macrogen said it would focus on diversifying its business portfolio by expanding its overseas base, introducing professional management systems and experts, establishing global direct-to-consumer (DTC) personal genetic testing, and developing medical institution-linked disease prediction screening, clinical diagnosis, and single-cell analysis.

Specifically, the company plans to expand its European bases from four to 10 this year. It has already established French and Polish branches to target the European market and a Chilean branch as a beachhead for the South American market.

Moreover, the company plans to strengthen efforts to successfully expand its portfolio of B2B2C (business to business to consumer) services through corporate partnerships, such as B2C and Bank Salad, including DTC genetic testing, and specialized technologies, such as single-cell analysis.

Based on the Macrogen Medical Foundation's Gene Health Examination Center, it will expand the network of customer hospitals and examination centers for disease prediction gene customization and liquid biopsy cancer diagnosis panel services nationwide while also expanding vertical integration by expanding forward businesses such as materials and reagents.

Furthermore, Macrogen plans to complete the "Global Genome Campus" in Songdo, Incheon, by 2025, which will be Asia's largest global genetic big data platform, and promote automation and intelligence of the genetic analysis process based on mid- to long-term cooperation activities.

Its strategy is to prepare for a shift in the individual-led health care paradigm, such as the popularization of personal genetic tests, by enhancing the competitiveness of "Genome Foundry" and introducing genetic analysis process automation and artificial intelligence (AI) solutions for the first time in the industry, according to Macrogen.

“As the era of personalized medicine approaches, we will build big data that integrates health information and genetic information to provide personalized genetic counseling through artificial intelligence (AI) solutions that can predict diseases and provide personalized health care." Co-CEOs Kim Chang-hoon and CEO Lee Soo-gang said.